3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Other hematologic neoplasm
1
Gastrointestinal
1
CNS
1
Conditions
Neoplasms by Site
2
Neoplasms by Histologic Type
2
Neoplasms
2
Hematologic Neoplasms
2
Stomach Neoplasms
1
Sarcoma
1
Neuroblastoma
1
Lymphoproliferative Disorders
1
Glioma
1
Interventions
Oxaliplatin
11
Docetaxel
8
Fluorouracil
6
Capecitabine
6
Leucovorin
5
Drug Therapy
5
apatinib
4
Trastuzumab
4
S 1 (combination)
4
Tegafur
3
Paclitaxel
3
Nivolumab
3
Irinotecan
3
Cisplatin
3
sintilimab
2
disitamab vedotin
2
Surgical Procedures, Operative
2
Standard of Care
2
Ramucirumab
2
Hyperthermic Intraperitoneal Chemotherapy
2
Epirubicin
2
vinflunine
1
toripalimab
1
titanium silicide
1
tislelizumab
1
taxane
1
polysaccharide-K
1
pertuzumab
1
margetuximab
1
gimeracil
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
Stomach Neoplasms
×
capmatinib
×
Clear all
NCT06988475
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled